Weight management
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading’ patients
Hims & Hers is facing scrutiny from lawmakers over an advertisement for its weight loss offerings that’s slated to run during the Super Bowl on Sunday. Sens. Dick Durbin, D-Ill., and Roger Marshall, R-Kan., wrote a letter to the U.S. Food and Drug Administration on Friday expressing concerns over an “upcoming advertisement” that “risks misleading […]
Read More
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does not cover it. Baillies, […]
Read More
The weight-loss drug boom has become one of the internet’s biggest scams
A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024. Bloomberg | Bloomberg | Getty Images One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case […]
Read More
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters Prescription fills for blockbuster weight loss drugs in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments, according to data released Thursday […]
Read More
Eli Lilly’s Zepbound causes greater weight loss than Novo Nordisk’s Wegovy in head-to-head trial
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk‘s Wegovy, in the first head-to-head clinical trial on the weekly injections. The […]
Read More
Novo Nordisk’s diabetes drug Ozempic may reduce the risk of Alzheimer’s disease, study says
Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk‘s blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer’s disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk […]
Read More
Port strike fallout: Blockbuster weight-loss drug supply from Wegovy to Ozempic, Mounjaro, Zepbound, caught up in East Coast trade shutdown
An Eli Lilly & Co. Zepbound injection pen, March 28, 2024. Bloomberg | Bloomberg | Getty Images As a port strike stretching from New England to Texas halted nearly half of all trade coming into the U.S., customs data shows that critical medical devices and drug components for the booming, expensive weight-loss and diabetes drugs […]
Read More
Digital health company Noom to offer compounded GLP-1 drug through new weight loss program
Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149. The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk’s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight loss programs for years, […]
Read More
This ETF is trying to satisfy appetites for bodyweight decline shares
ETF Edge This ETF is seeking to fulfill appetites for weight loss shares Released Sat, Jul 6 202411:00 AM EDT Ellie Stevens@elliestevens02 Enjoy Are living Supply
Read More
Why half of all workers may struggle to get weight-loss drug health insurance coverage
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses and their workers are often stuck […]
Read More